AstraZeneca eyes a safer PARP inhibitor, with nearly 50% response in advanced breast cancer patients: #AACR24

SAN DIEGO — AstraZeneca’s experimental PARP1 inhibitorPARP1 inhibitor helped shrink tumors in nearly half of people with breast cancers harboring certain DNA repair defects in an early-stage study.

The drug, saruparib, is the most advanced candidate in a new class of compounds that takes aim at the DNA repair enzyme.

While there are several PARP inhibitorsPARP inhibitors already on the market, including AstraZeneca and Merck’s Lynparza and Pfizer’s Talzenna, they target two similar enzymes, PARP1 and PARP2, and cause side effects like nausea, anemia and low white blood cell counts.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。